Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Aniridia-intellectual disability syndrome is an extremely rare autosomal dominant developmental defect of the eye described in several members of one family that is characterized by the association of moderate intellectual disability with aniridia, lens dislocation, optic nerve hypoplasia and cataracts. There have been no further descriptions in the literature since 1974.
Biomarker and diagnostic research for aniridia - intellectual disability syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
146 publications have been identified in PubMed for aniridia - intellectual disability syndrome. Research spans Review / Meta-Analysis (64%), Basic Science / Preclinical (16%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 94 | 64% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:59 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 24 | 16% |
Disease patterns and progression | 11 | 8% |
Patient case studies | 10 | 7% |
Testing and diagnosis research | 4 | 3% |
Other research | 2 | 1% |
Clinical study results | 1 | 1% |
Ferri C (2026). [PMID: 41798958](https://pubmed.ncbi.nlm.nih.gov/41798958/). *Front Immunol*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Lee S (2026). [PMID: 41206258](https://pubmed.ncbi.nlm.nih.gov/41206258/). *Am J Geriatr Psychiatry*. [Review / Meta-Analysis]
Lithoxopoulou M (2026). [PMID: 42111224](https://pubmed.ncbi.nlm.nih.gov/42111224/). *Mol Syndromol*. [Review / Meta-Analysis]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Ma R (2025). [PMID: 40992234](https://pubmed.ncbi.nlm.nih.gov/40992234/). *J Clin Anesth*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leuk Lymphoma*. [Review / Meta-Analysis]
Garcia-Diez AI (2025). [PMID: 40610162](https://pubmed.ncbi.nlm.nih.gov/40610162/). *Magn Reson Imaging Clin N Am*. [Review / Meta-Analysis]
Brokke KE (2025). [PMID: 40634186](https://pubmed.ncbi.nlm.nih.gov/40634186/). *Br J Anaesth*. [Review / Meta-Analysis]